Serbian bioengineering SME specializing in computational simulation of cardiovascular devices, in-silico clinical trials, and medical VR/AR visualization.
BioIRC is a Serbian bioengineering R&D company specializing in computational modeling and in-silico simulation of cardiovascular diseases and medical devices. They build digital tools — from computational fluid dynamics models to VR/AR visualization platforms — that help predict how drugs, stents, and coated balloons behave in the human body before physical trials. Their work sits at the intersection of biomedical engineering and clinical decision support, with particular strength in simulating blood flow, drug delivery mechanisms, and patient stratification for cardiovascular conditions.
Core contributor across InSilc (drug-eluting stent simulation), SILICOFCM (cardiomyopathy drug tracing), TAXINOMISIS (carotid artery stratification), and DECODE (drug-coated balloon optimization).
InSilc focused on bioresorbable vascular scaffolds, SILICOFCM on sarcomeric protein mutations, and DECODE on drug-coated balloon simulation and optimization.
HOLOBALANCE developed hologram-based physiotherapy coaching, and DECODE included VR and AR visualization components for clinical training.
HarmonicSS involved big data mining across Sjögren syndrome cohorts, while TAXINOMISIS applied omics and pharmacogenomics for carotid artery patient stratification.
DECODE explicitly includes cloud platform design and integration for drug-coated balloon simulation systems.
BioIRC's early work (2017-2018) was broader, spanning autoimmune disease data analytics (HarmonicSS), augmented reality for elderly balance therapy (HOLOBALANCE), and initial cardiovascular device simulation (InSilc). From 2018 onward, their focus sharpened decisively toward computational cardiovascular modeling — carotid artery stratification, familial cardiomyopathy simulation, and drug-coated balloon optimization. The trajectory shows a company that tested several bioengineering niches early on and then doubled down on in-silico trials for cardiovascular devices and treatments.
BioIRC is consolidating around computational simulation of cardiovascular interventions with growing capability in cloud deployment and immersive visualization, positioning them as a go-to partner for digital twin approaches in vascular medicine.
BioIRC operates predominantly as a specialist partner (5 of 6 projects), contributing computational modeling expertise to larger consortia. They coordinated one significant project (SILICOFCM, their largest at EUR 721K), demonstrating they can lead when the topic is squarely in their core domain. With 86 unique partners across 18 countries, they maintain a wide European network rather than relying on repeat partnerships — a sign of a technically valued contributor that different groups want on their team.
BioIRC has collaborated with 86 distinct partners across 18 countries, indicating strong pan-European reach for a Serbian SME. Their network spans clinical centers, universities, and tech companies involved in health research, with no obvious geographic cluster beyond broad EU engagement.
BioIRC is one of very few Serbian SMEs with deep, consistent participation in EU health research — six H2020 projects and nearly EUR 2.6M in funding is exceptional for a private company from a non-EU member state. Their specific combination of computational fluid dynamics, medical device simulation, and VR visualization is rare; most in-silico medicine players are either large research institutes or university labs, not agile private companies. For consortium builders, they offer serious modeling capability with SME flexibility and competitive cost structures from the Western Balkans.
